Development of the Inactivated QazCovid-in Vaccine: Protective Efficacy of the Vaccine in Syrian Hamsters

@article{Zhugunissov2021DevelopmentOT,
  title={Development of the Inactivated QazCovid-in Vaccine: Protective Efficacy of the Vaccine in Syrian Hamsters},
  author={Kuandyk Zhugunissov and Kunsulu D Zakarya and Berik Khairullin and Mukhit B. Orynbayev and Yergali Abduraimov and Markhabat Kassenov and Kulyaisan T Sultankulova and Aslan Kerimbayev and Sergazy Nurabayev and Balzhan Myrzhakhmetova and Aziz Nakhanov and Ainur Nurpeisova and Olga V. Chervyakova and Nurika Assanzhanova and Yerbol Burashev and Muratbay Mambetaliev and Moldir Azanbekova and Syrym Kopeyev and Nurlan Kozhabergenov and Aisha U Issabek and Moldir Tuyskanova and Lespek Kutumbetov},
  journal={bioRxiv},
  year={2021}
}
In March 2020, the first cases of human coronavirus infection COVID-19 were registered in Kazakhstan. We isolated the SARS-CoV-2 virus from the clinical material from the patients. Subsequently, a whole virion inactivated candidate vaccine, QazCovid-in, was developed based on this virus. To obtain the vaccine, a virus grown in Vero cell culture was used, which was inactivated with formaldehyde, purified, concentrated, sterilized by filtration, and then sorbed on aluminum hydroxide gel particles… 
3 Citations
An overview on inactivated and live‐attenuated SARS‐CoV‐2 vaccines
TLDR
This study has a review on inactivated SARS‐CoV‐2 vaccines that are passing their phase 3 and 4 clinical trials, population which was included in the trials, vaccine producers, the efficiency, adverse effects, and components of vaccines, and other vaccine features.

References

SHOWING 1-10 OF 59 REFERENCES
Protective Efficacy of Inactivated Vaccine against SARS-CoV-2 Infection in Mice and Non-Human Primates
TLDR
The data showed that the inactivated vaccine successfully induced SARS-CoV-2-specific neutralizing antibodies in mice and non-human primates, and subsequently provided partial (in low dose) or full (in high dose) protection of challenge in the tested animals.
Immunogenicity and protective efficacy in mice and hamsters of a β-propiolactone inactivated whole virus SARS-CoV vaccine.
TLDR
Enhanced disease was not observed in the lungs or liver of hamsters following SARS-CoV challenge, regardless of the level of serum neutralizing antibodies, and vaccine with adjuvant provided better protection than non-adjuvanted WI-SARS vaccine at this later time point.
Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies
TLDR
A whole virus NRC-VACC-01 inactivated candidate SARS-CoV-2 vaccine was developed and tested its safety and immunogenicity in laboratory animals and it was revealed that the vaccine was highly tolerable.
Development of an inactivated vaccine candidate for SARS-CoV-2
TLDR
Preclinical results of an early vaccine candidate called PiCoVacc, which protected rhesus macaque monkeys against SARS-CoV-2 infection when analyzed in short-term studies, support the clinical development and testing of Pi coVacc for use in humans.
Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus
TLDR
These SARS-CoV vaccines all induced antibody and protection against infection with SARS -CoV, however, challenge of mice given any of the vaccines led to occurrence of Th2-type immunopathology suggesting hypersensitivity to SARsCoV components was induced.
Preclinical efficacy and safety analysis of gamma-irradiated inactivated SARS-CoV-2 vaccine candidates
TLDR
This study shows that the vaccines are effective and leads us to start the challenge test to investigate the gamma-irradiated inactivated vaccine candidates for infective SARS-CoV-2 virus in humanized ACE2+ mice.
Preclinical efficacy and safety analysis of gamma-irradiated inactivated SARS-CoV-2 vaccine candidates
TLDR
This study shows that the vaccines are effective and leads us to start the challenge test to investigate the gamma-irradiated inactivated vaccine candidates for infective SARS-CoV-2 virus in humanized ACE2 + mice.
Effect of inactivation method on the cross-protective immunity induced by whole 'killed' influenza A viruses and commercial vaccine preparations.
TLDR
A single dose of gamma-ray-inactivated A/PC (gamma-A/PC) conferred significant protection in mice against both homologous and heterosubtypic virus challenges and elicited cytotoxic T-cell responses that are most likely responsible for the cross-protective and long-lasting immunity against highly lethal influenza A infections in mice.
Efficacy of inactivated poliovirus vaccine in India
TLDR
Controversy over vaccine choice for polio eradication can be reconciled by effective combined use of IPV and Sabin together, and IPV in OPV-vaccinated individuals boosts intestinal mucosal immunity.
...
...